Business Description
Healios KK
ISIN : JP3835100003
Total Employee Number:
102Description
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.2 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | -1.31 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.1 | |||||
Beneish M-Score | 19.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10 | |||||
3-Year EBITDA Growth Rate | 38.3 | |||||
3-Year EPS without NRI Growth Rate | 33.6 | |||||
3-Year FCF Growth Rate | 24.4 | |||||
3-Year Book Growth Rate | -15.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 300.23 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.03 | |||||
9-Day RSI | 0.9 | |||||
14-Day RSI | 4.71 | |||||
3-1 Month Momentum % | -33.33 | |||||
6-1 Month Momentum % | -6.74 | |||||
12-1 Month Momentum % | -43.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.05 | |||||
Quick Ratio | 2.05 | |||||
Cash Ratio | 1.88 | |||||
Days Sales Outstanding | 1058.5 | |||||
Days Payable | 526.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.3 | |||||
Shareholder Yield % | -23.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -155.41 | |||||
Operating Margin % | -5035.14 | |||||
Net Margin % | -4233.78 | |||||
EBITDA Margin % | -2679.73 | |||||
FCF Margin % | -5171.63 | |||||
OCF Margin % | -4916.53 | |||||
ROE % | -84.3 | |||||
ROA % | -17.33 | |||||
ROIC % | -24.33 | |||||
3-Year ROIIC % | 49.91 | |||||
ROC (Joel Greenblatt) % | -232.08 | |||||
ROCE % | -17.52 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 352.94 | |||||
PB Ratio | 4.4 | |||||
Price-to-Tangible-Book | 10.59 | |||||
EV-to-EBIT | -11.04 | |||||
EV-to-EBITDA | -12.59 | |||||
EV-to-Revenue | 337.3 | |||||
EV-to-FCF | -6.46 | |||||
Price-to-GF-Value | 4.29 | |||||
Earnings Yield (Greenblatt) % | -9.06 | |||||
FCF Yield % | -11.64 |
Healios KK Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Healios KK Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guru Commentaries on OTCPK:HLOSF
No articles.
Press Release
Articles on Healios KK
No articles.